Pamidronate Disodium Tillomed Laboratories (Pamidronate Disodium)

Pamidronate disodium is a bisphosphonate that acts on skeletal metabolism to reduce pathological bone turnover.

• Hypercalcaemia of malignancy: lowers serum calcium levels and alleviates related symptoms.
• Osteolytic bone metastases: helps preserve bone density and reduces skeletal‑related events.
• Paget’s disease of bone: moderates abnormal bone remodeling and pain.
• Prevention of bone loss after stem‑cell transplantation: supports bone mineral density during recovery.

• Pamidronate disodium binds with high affinity to hydroxy‑apatite crystals on bone surfaces, especially at sites of active remodeling. Once internalised by osteoclasts, it inhibits farnesyl pyrophosphate synthase within the mevalonate pathway, disrupting prenylation of small G‑proteins essential for osteoclast attachment, ruffling, and resorption activity, thereby reducing bone breakdown.

Adverse reactions to pamidronate are reported across a spectrum of frequency.

Common Side Effects

• Acute phase reaction (fever, myalgia, arthralgia)
• Nausea or vomiting
• Transient hypocalcaemia
• Headache
• Injection site discomfort

Serious or Rare Side Effects

• Renal impairment or acute tubular necrosis
• Severe hypocalcaemia with tetany
• Atypical femoral fractures
• Osteonecrosis of the jaw (ONJ)
• Hypersensitivity reactions including anaphylaxis

When using pamidronate, clinicians should assess patient‑specific risk factors and monitor relevant laboratory parameters.

• Renal function: evaluate serum creatinine and adjust infusion rate in renal impairment.
• Calcium & vitamin D status: correct deficiencies before infusion to reduce hypocalcaemia risk.
• Concomitant nephrotoxic drugs: avoid or space administration.
• Pregnancy & lactation: use only if clearly indicated, after risk‑benefit evaluation.
• Long‑term therapy: monitor for signs of atypical fractures or jaw osteonecrosis.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Pamidcinate may interact with several co‑administered agents; careful review is advised.

Major Interactions (Avoid)

• Concurrent high‑dose intravenous bisphosphonates: additive renal toxicity.
• Aminoglycoside antibiotics (e.g., gentamicin): increased risk of nephrotoxicity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) in patients with compromised renal function: heightened renal adverse events.

Moderate Interactions (Monitor Closely)

• Calcium‑containing antacids or supplements taken within 4 h of infusion: may reduce pamidronate absorption onto bone.
• Loop diuretics: may potentiate hypocalcaemia.
• Corticosteroids: may exacerbate bone loss if used long‑term.
• Vitamin D analogues: require monitoring of calcium levels.
• Anticoagulants (e.g., warfarin): monitor INR as bone turnover changes can affect vitamin K‑dependent pathways.